Investors spooked by Abcam results

Investors spooked by Abcam results

A 20 per cent six-month share price rise and a valuation of 50 times forward earnings probably demanded more than just an 'in line' set of annual numbers. But the Abcam (ABC) share price slump on release of these results looked a tad overdone. After all, management still expects low, double-digit revenue growth over the medium term as the group outpaces strong global growth in the antibody market.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now